ClinicalTrials.gg
RecruitingNCT04025541ALCINA2Updated Nov 9, 2026

Analysis of Circulating Tumor Markers in Blood

An interventional study of Blood sampling and Blood sampling C3 in Cancer, Breast Cancer and Sarcoma, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Diagnostic

How we know · 3 judgments

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled May 2018, registered Jun 2019).
  • Started May 2018; still recruiting 8 years 5 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
992
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Read the detailed description

The new major challenge in the research concerns the circulating biomarkers, which aim at replacing the molecular analyses on tumour tissue obtained by biopsy (for example the search for somatic mutations of cancer) by a simple blood test (liquid biopsy). The other current important challenge is to have an idea of the interest to analyse the kinetics of blood markers, in particular in answer to a clinical "event", either through the chemotherapy, a biopsy and / or surgery. There is almost no data in the literature on this aspect. It is very likely that the liberation in the blood of the blood tumoral markers is strongly dependent on medical interventions on the tumour.

The study ALCINA 2 rests exactly on the principle of small cohorts, which correspond each to a clinical situation and/or a technique of different implemented detection, so as to generate data of feasibility and proof of concept. In case of success, statistical hypotheses will be necessary for the implementation of wider studies (being then the object of a specific approval by competent authorities).

02

Conditions studied

  • Cancer
  • Breast Cancer
  • Sarcoma
  • Lung Cancers
  • Glioma
  • Colon Cancer
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 992 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
  2. Man or woman ≥ 18 years,
  3. Obtaining of the signed before any procedure of specific preselection on approval.

Exclusion criteria

Exclusion Criteria:

  1. Private persons of freedom or under guardianship,
  2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
  3. Pregnant woman and/or breast-feeding,
  4. Unaffiliated patient to Social Protection System,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
992 participants (estimated)

Study arms

  • Other
    COHORT 1 BREAST TUMOR/PALBOCICLIB

    Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib BLOOD SAMPLING

    Biological: Blood sampling

  • Other
    COHORT 2 BREAST TUMOR / RIBOCICLIB

    Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib BLOOD SAMPLING

    Biological: Blood sampling

  • Other
    COHORT 3 - LUNG CANCER

    Patients with histologically proven metastatic bronchial carcinoma eligible for immunotherapy

    Biological: Blood sampling C3

  • Other
    COHORT 4 - CCRm

    Patient with metastatic colorectal adenocarcinoma

    Biological: Blood sampling C4/7/10/13

  • Other
    COHORT 5 - T-DXd

    Patient with HER2 + metastatic breast cancer, requiring treatment with T-DXd

    Biological: Blood sampling C5

  • Other
    COHORT 6 - Glioma

    Patient with grade II, III or IV diffuse glioma

    Biological: Blood sampling C6

  • Other
    COHORT 7 - CIRCUS 2

    Patients with non-metastatic colon cancer

    Biological: Blood sampling C4/7/10/13

  • Other
    COHORT 8 - CTC-AXL Breast

    Patients with treatment-naive metastatic breast cancer with distant metastases

    Biological: Blood sampling C8

  • Other
    COHORT 9 - ImmunoTNBC

    Patients newly diagnosed with non-metastatic stage II - III early TNBC, requiring neoadjuvant treatment and previously untreated.

    Biological: Blood sampling C9

  • Other
    COHORT 10 - LPS

    Patients with well differentiated (WD) liposarcoma, dedifferentiated (DD) liposarcoma or sarcoma other than liposarcoma

    Biological: Blood sampling C4/7/10/13

  • Other
    COHORT 11 - LUNG DRIVER

    Patients with Metastatic bronchial carcinoma activating alterations in EGFR (del 19; L858R) or KRAS G12C

    Biological: Blood sampling C11 + FFPE

  • Other
    COHORT 12 - LMD

    Patient with breast cancer and suspected with leptomeningeal metastases

    Biological: Blood sampling C12

  • Other
    COHORT 13 - RILA STAB

    Patients with breast cancer requiring radiotherapy, whatever the tumor stage

    Biological: Blood sampling C4/7/10/13

Interventions

  • BiologicalBlood sampling

    blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time

    Also known as: Tumor sampling

  • BiologicalBlood sampling C3

    Blood samples will be collected at four key time points: * baseline (T1), * first scan assessment (T2), * second scan assessment (T3), * and progression (T4).

  • BiologicalBlood sampling C4/7/10/13

    Blood samples will be collected before any treatment

  • BiologicalBlood sampling C5

    Blood samples will be collected at four key time points: * At the inclusion (T1) * Before the beginning of the treatment (cycle 1 day 1) (T2) * After the first cycle of T-DXd (cycle 2 day 1) (T3) * At progression or at the end of the follow-up (after 3 years) (T4)

  • BiologicalBlood sampling C6

    Blood samples will be collected at three key time points: * At the inclusion (T1) * For patients starting treatment at the time of inclusion (T2): * Chemotherapy: 3 months after inclusion, * Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy, * For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3).

  • BiologicalBlood sampling C8

    Blood samples will be collected at five key time points: * At the inclusion * At follow-up visit 2 to 6, every 3 months

  • BiologicalBlood sampling C9

    Blood samples will be collected at four key time points: * At the inclusion before the beginning of the treatment (Cycle 1 Day 1) * After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1) * After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1) * After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery

  • BiologicalBlood sampling C11 + FFPE

    Blood samples will be collected at five key time points: * At the inclusion (T1) * At first clinical evaluation (T2): 4th week after start of treatment * At first scan evaluation (T3a): 8th week after start of treatment * At the Nth scan evaluation (T3b, c, ...) * At progression (T4) Tumor sampling : * At the inclusion * At tumor progression

  • BiologicalBlood sampling C12

    Blood samples will be collected at several points : * Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment, * Every 4 weeks until meningeal progression, or for a maximum of 4 months, * Then every 3 months beyond 4 months until meningeal progression.

This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Estimation of the feasibility of the various blood tumoral biomarkers analysis

    Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients"

    Time frame: 4 YEARS

Secondary outcomes

  1. COHORT 1 and 2 : rate of patients with a grade 3-4 of neutropenia Ciclib-related

    Number of participants with treatment-related neutropenia as assessed by CTCAE v4.03

    Time frame: 4 YEARS

  2. COHORT 1 and 2 : rate of patients with a hepatic toxicity Ciclib-related

    Number of participants with treatment-related hepatic toxicity as assessed by CTCAE v4.03

    Time frame: 4 YEARS

  3. COHORT 3 : Correlation between response to immunotherapy (progressive versus non-progressive) and the number of circulating tumour cells (CTC) expressing the PDL1 marker at T1 (baseline)

    Number of CTCs expressing PDL1 at T1

    Time frame: 4 years

  4. COHORT 4 : To compare the expression of the circulating MS9 mRNA biomarker between healthy subjects and treatment-naive patients with metastatic colorectal cancer

    Expression of the MS9 mRNA biomarker

    Time frame: 1 year

  5. COHORT 5 : to study the impact of baseline HER2+ CTCs detection on PFS under T-DXd treatment

    Progression-Free Survival (the primary outcome measure being the HR between CTC+ and CTC- patients, using the HER2+ CTC count at baseline)

    Time frame: 4 years

  6. COHORT 6 : To develop a computerised procedure for diagnosing glioma based on a nucleoside profile obtained by mass spectroscopy, using Artificial Intelligence

    Positive predictive value and negative predictive value of the signature to discriminate glioma vs. no glioma

    Time frame: 4 years

  7. COHORT 7 : to optimise the culture of circulating tumour cells (CTCs)

    Median number of CTCs 1 month after inclusion

    Time frame: 4 years

  8. COHORT 8 : to evaluate the concordance of CTC-AXL measurement (at inclusion) using the innovative EPIDROP technique and the CellSearch technique

    Concordance rate of CTC-AXL measurement (at inclusion) by EPIDROP technique (AXL(-): 0 vs AXL(+): ≥1) and CellSearch technique (AXL(-): 0 vs AXL(+): ≥1)

    Time frame: 4 years

  9. COHORT 9 : to evaluate the predictive value of circulating immune populations for response to neo-adjuvant chemo-immunotherapy (according to pCR) in patients with early TNBCs, by performing an immunomonitoring before, during and after the treatment.

    Response to treatment is defined as a pathological complete response (i.e. no residual invasive tumor in breast and axillary lymph nodes (ypT0ypN0)) after neo-adjuvant therapy.

    Time frame: 4 years

  10. COHORT 10 : to identify a new non-invasive biological test for the diagnosis of LPS by measuring MDM2 DNA in circulating vesicles

    Sensibility and specificity of circulating MDM2 DNA in circulating vesicles for LPS diagnosis

    Time frame: 4 years

  11. COHORT 11 : to demonstrate a correlation between tumour progression under targeted therapy against EGFR (DEL19; L858R), KRAS G12C and the number of CTCs expressing the HES 1 marker at progression (T4)

    Number of CTCs expressing HES 1 to T4

    Time frame: 4 years

  12. COHORT 12 : to assess the sensitivity of the hepcidin assay in blood for the diagnosis of leptomeningeal metastases of breast cancer, the gold standard being cytological examination of CSF (up to 3 samples).

    Sensitivity of the hepcidin value in the 1st blood sample for the diagnosis of leptomeningeal metastases

    Time frame: 4 years

  13. COHORT 13 : to validate the stability of the RILA at 24hrs (D1), 48hrs (D2), 72hrs (D3) and 96hrs (D4)

    The mean RILA at 24h (D1), 48h (D2), 72h (D3) and 96h (D4) will be compared. Equivalences between conditions ((1) 24h and 48h, (2) 24h and 72h, (3) 24h and 96h) will be assessed using Passing \& Bablok regression and/or paired t-test. Also, linear regressions between 24h, 48h, 72h and 96h for the same patients will be evaluated in order to determine, if necessary, a conversion formula.

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Bardol T, Eslami-S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, Bobrie A, D'Hondt V, Guiu S, Kurma K, Cayrefourcq L, Jacot W, Alix-Panabieres C. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study. Cancer Med. 2024 Jan;13(1):e6843. doi: 10.1002/cam4.6843. Epub 2023 Dec 22. PubMed 38132919 ↗
  • Leenhardt F, Fiteni F, Gauthier L, Alexandre M, Guiu S, Firmin N, Pouderoux S, Viala M, Lossaint G, Gautier C, Mollevi C, Gracia M, Gongora C, Mbatchi L, Evrard A, Jacot W. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. Pharmaceutics. 2022 Apr 11;14(4):841. doi: 10.3390/pharmaceutics14040841. PubMed 35456675 ↗
  • Leenhardt F, Alexandre M, Guiu S, Pouderoux S, Beaujouin M, Lossaint G, Philibert L, Evrard A, Jacot W. Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy. Cancer Chemother Pharmacol. 2021 Oct;88(4):723-729. doi: 10.1007/s00280-021-04331-0. Epub 2021 Jul 20. PubMed 34286354 ↗
  • Leenhardt F, Gracia M, Perrin C, Muracciole-Bich C, Marion B, Roques C, Alexandre M, Firmin N, Pouderoux S, Mbatchi L, Gongora C, Jacot W, Evrard A. Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction. J Pharm Biomed Anal. 2020 Sep 5;188:113438. doi: 10.1016/j.jpba.2020.113438. Epub 2020 Jun 22. PubMed 32623316 ↗
  • Leenhardt F, Jacot W, Lellouche L, Guiu S, Viala M, Firmin N, Payen A, Mbatchi LC, Fiteni F, Evrard A. Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib. Breast Cancer Res Treat. 2026 Jul 28;218(2):20. doi: 10.1007/s10549-026-08041-0. PubMed 42521839 ↗
  • Kurma K, Bardol T, Mollevi C, Eslami-S Z, Garima F, Alexandre M, Bobrie A, Lossaint G, Massemin B, D'Hondt V, Guiu S, Cayrefourcq L, Jacot W, Alix-Panabieres C. Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer. J Exp Clin Cancer Res. 2026 Apr 18;45(1):111. doi: 10.1186/s13046-026-03709-3. PubMed 42001180 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for May 2029, 132 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 132 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion May 2026 → May 2029 and completion May 2029 → May 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jul 19, 2019
StartActual
May 29, 2018
Primary completionEst.
May 29, 2029was May 2026
CompletionEst.
May 29, 2032was May 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 29, 2026→May 29, 2029
Nov 9, 2026
Study completion
May 29, 2029→May 29, 2032
Nov 9, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42521839 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42521839 ↗
    Primary completion May 29, 2026→May 29, 2029
    Study completion May 29, 2029→May 29, 2032
    + 3 other changes: verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04025541
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
May 29, 2018
Primary completion
May 29, 2029 (estimated)
Completion
May 29, 2032 (estimated)
Last update
Nov 9, 2026

Study contacts

texier emmannuelle
Contact
emmanuelle.texier@icm.unicancer.fr
0467613102

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion